A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...

Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.

Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...

The Therapeutic Goods Administration (TGA) has made the decision not to register lecanemab (LEQEMBI) for the treatment of ...

New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...

While Alzheimer’s can’t be reversed, Leqembi has proven that it can slow down the progression of the disease.

Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...

A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...

An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...

A recent study supported by the National Institutes of Health (NIH) and published in Nature Neuroscience found that Alzheimer ...

When Dennis Carr learned he had early Alzheimer’s disease, he immediately thought of his older brother who had died of the illness in 2023. “There was not much anyone could do,” Carr said of ...

The earlier MCI due to AD and mild AD dementia are diagnosed and treated, the greater the opportunity for benefit [1] Last July, the U.S. Food and Drug Administration (FDA) issued a notable ...